Deep Apple Therapeutics CEO Spiros Liras (L) and interim CSO Paul Da Silva Jardine
December 14, 2023 07:30 AM EST
Financing
Startups
AI

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Kyle LaHucik

Senior Reporter

Two for­mer chem­istry VPs who worked at Pfiz­er’s car­dio­vas­cu­lar and meta­bol­ic re­search group have come to­geth­er to build a new biotech as the obe­si­ty drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times